Lyra Therapeutics Terminates Material Agreement
Ticker: LYRA · Form: 8-K · Filed: 2026-04-10T08:59:10-04:00
Sentiment: neutral
Topics: termination, agreement
TL;DR
Lyra Therapeutics just terminated a major deal, big implications ahead.
AI Summary
Lyra Therapeutics, Inc. filed an 8-K on April 10, 2026, to report the termination of a material definitive agreement. The filing does not specify the agreement or the parties involved, but it indicates a significant event has occurred that requires disclosure.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, financial standing, and future prospects, requiring investors to re-evaluate their positions.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals underlying issues or strategic shifts that could negatively affect the company's performance.
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Filer
- 0001327273 (company) — CIK Number
- 0001193125-26-150441 (filing_id) — SEC Accession Number
- 2026-04-10 (date) — Filing Date
FAQ
What specific material definitive agreement was terminated by Lyra Therapeutics?
The provided 8-K filing does not specify the name or details of the material definitive agreement that was terminated.
Who were the other parties involved in the terminated agreement?
The filing does not disclose the identity of the other parties to the terminated material definitive agreement.
What is the effective date of the termination of the material definitive agreement?
The filing indicates the period of report ended on March 31, 2026, and the filing date was April 10, 2026, but does not explicitly state the termination effective date.
What are the potential financial or operational impacts of this termination on Lyra Therapeutics?
The filing does not detail the specific financial or operational impacts resulting from the termination of the material definitive agreement.
Why did Lyra Therapeutics terminate this material definitive agreement?
The reasons for the termination of the material definitive agreement are not provided in this 8-K filing.
From the Filing
EDGAR Filing Documents for 0001193125-26-150441 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-150441 Filing Date 2026-04-10 Accepted 2026-04-10 08:59:10 Documents 11 Period of Report 2026-03-31 Items Item 1.02: Termination of a Material Definitive Agreement Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d345211d8k.htm iXBRL 8-K 24309 Complete submission text file 0001193125-26-150441.txt 134580 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA lyra-20260331.xsd EX-101.SCH 2863 3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyra-20260331_lab.xml EX-101.LAB 17233 4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyra-20260331_pre.xml EX-101.PRE 10820 15 EXTRACTED XBRL INSTANCE DOCUMENT d345211d8k_htm.xml XML 3532 Mailing Address 480 ARSENAL WAY WATERTOWN MA 02472 Business Address 480 ARSENAL WAY WATERTOWN MA 02472 617-373-4600 Lyra Therapeutics, Inc. (Filer) CIK : 0001327273 (see all company filings) EIN. : 000000000 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-39273 | Film No.: 26853293 SIC : 3841 Surgical & Medical Instruments & Apparatus (CF Office: 08 Industrial Applications and Services)